Malignant astrocytoma remains incurable and rapidly fatal despite multimodal therapy. In particular, accelerated tumor cell heterogeneity often overcomes therapeutic effects of molecular protein targeting. This study aimed at identifying a gene with therapeutic potential that was consistently downregulated with astrocytoma progression. Analysis of the "Rembrandt" gene expression data revealed Wnt inhibitory factor 1 (WIF1) gene as the most promising candidate with tumor suppressor function. Consequently, 288 randomly selected tissue regions of astrocytoma specimens were investigated immunohistochemically with the aid of image analysis. This in situ approach identified tumor areas with numerous single cells strongly expressing Wif-1. In diffuse and anaplastic astrocytoma, the proliferation index was independent of the generally weak Wif-1 expression in tumor cells but was significantly correlated with the density of Wif-1-expressing single cells, subsequently characterized as native and non-neoplastic oligodendrocytes. Because these cells may contribute to inhibition of tumor cell proliferation by paracrine signaling, the endogenous protein Wif-1 may represent a promising therapeutic agent with expected minimal side effects. Moreover, we suggest that immunohistochemistry for Wif might be useful for discriminating between astrocytic tumors and reactive changes.
INTRODUCTION-1
Astrocytomas are the most common primary brain tumors. They are subclassified according to their biological behavior as pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, and glioblastoma (GBM) (WHO grades I-IV), with incidence rates of approximately 0.37, 1.4 and 3-4 per 100 000 person-years for WHO Grades I, II, and IV astrocytomas (1) .
Diffuse astrocytomas progress to anaplastic astrocytoma and GBM, ie, tumors that remain incurable and rapidly fatal despite multimodal therapies, which include surgery, radiation, and chemotherapy. This tumor dedifferentiation is accompanied by accelerated deregulation of gene expression levels and gene mutations (2) . One tool to screen for new therapeutic targets is gene expression profiling. Genes that are markedly upregulated in tumors compared with non-neoplastic tissue are potential candidates for direct protein targeting. However, heterogeneity of target expression can be accelerated in tumor cells and expression can be lost in tumor cell subpopulations as tumors progress; consequently, this leads to therapeutic escape.
To overcome these limitations, the present study was aimed at analyzing gene expression profiles to identify genes that are highly expressed in non-neoplastic brain, consistently downregulated at an early stage of astrocytoma (WHO Grade II) and not re-expressed in malignant astrocytoma (WHO Grade IV). Because promoter methylation is known to be an early carcinogenic event and demethylation is a rare occurrence in tumor progression (3), we suggested promoter methylation as an additional filter criterion. Moreover, we used tumor suppressor function as another filter criterion to narrow the search for a new candidate gene. Taking account of already published data, WIF1 was identified as the most promising gene for further analysis. To prove consistency of protein downregulation in situ and on single-cell level, protein expression was analyzed using immunohistochemistry and quantification by image analysis. To extend the concept, the antiproliferative potential of Wif-1was validated by Ki67 staining and subsequent correlation analyses.
MATERIALS AND METHODS

Gene Expression Analysis
Gene expression data were obtained from the public Rembrandt database (https://caintegrator.nci.nih.gov/rem brandt) (4) . Raw data of 128 astrocytomas (WHO Grades II and III), 191 GBMs, and 21 cerebral nontumor tissues were analyzed with bioconductor (www.bioconductor.org) packages "Affy," "Annotate," and "hgu133plus2.db" in R software environment (5) (6) (7) (8) .
Data were preprocessed and normalized with the "Affy" package. Genes significantly downregulated in diffuse astrocytoma and in GBM compared with non-neoplastic brain tissue were identified by Mann-Whitney U-tests. This gene set was filtered by a panel of 24 well-characterized genes with tumor suppressor function and DNA methylation of a PCR methylation array (www.sabiosciences.com). GO terms (geneontology.org) were not appropriate for this approach because the term "tumor suppressor function" was obsolete and "DNA methylation" referred to gene function. The expression levels of the resulting small gene set were analyzed with box plots to identify the most consistently downregulated genes for literature search and subsequently the candidate gene for detailed analysis.
Sample Collection
In accordance with the local ethical standards, 115 formalin fixed paraffin-embedded tissue samples of human astrocytoma and oligodendroglioma, surgically dissected at the Department of Neurosurgery, Medical University of Graz, Austria between 2004 and 2007 were provided by the Institute of Pathology, Medical University of Graz. The formalin fixed paraffin-embedded samples of 15 pilocytic astrocytomas, 35 diffuse astrocytomas, 25 anaplastic astrocytomas, 30 GBMs, and 10 oligodendrogliomas (WHO Grades II and III) were reviewed by a neuropathologist according to the representative tumor content.
Three hundred fifty randomly selected tissue areas in astrocytomas and 20 areas in oligodendrogliomas were marked on hematoxylin and eosin (H&E)-stained slides. Each area of 5-mm diameter was graded according to WHO criteria separately by a neuropathologist. The tumor regions were classified as tumor center, invasion margin, and non-neoplastic brain tissue.
Immunohistochemistry
Staining with anti-Wif-1 antibody (Cat. No. ab105925, Abcam, Cambridge, UK) and anti-Iba-1 antibody (Cat. No. ab15690, Abcam) was performed with Leica BondTM Max Autostainer (Leica Biosystems, Melbourne, Australia). Slides were barcoded, sections deparaffinized at 60 C for 30 min and stained following a standard protocol. Anti-Wif-1 andIba-1 antibodies were used in a 1:2000 dilution with Bond Primary Antibody diluent (Cat. No. AR9352, Leica, UK). BondTM Polymer Refine Detection (Cat. No. DS9800, Leica) was used as a detection system. The program IHC-30 was applied according to the manufacturer's recommendations (antigen retrieval with ER1 for 10 min, solutions provided by the manufacturer).
Immunohistochemistry for Ki67, MAP-2 and IDH1 (R132H) was performed on a Ventana Autostainer Ultra (Ki67, IDH1R132H) (Ventana, Tucson, AZ) and Dako Autostainer (MAP-2) (Dako, Vienna, Austria). The Ki67 
Imaging
The regions of interest (ROIs), which were randomly selected on H&E-stained slides, were translated on the anti-Wif-1 and -Ki67 stained sections. Using an Eclipse 80i microscope with a 20Â objective, marked areas were captured with Digital sight DS-Fi1 camera and NIS-Elements D software (Version 3.21.04, Nikon, Japan) with the same correction for brightness and white balance. In total, 288 areas passed visual quality control of reliable staining with both antibodies for image analysis.
Quantification of Immunohistochemical Staining
JPG images were generally processed in RGB color mode. The automated image analysis procedure was performed with "EBImage" package (9) from bioconductor (www. bioconductor.org) and cell counting was done in ImageJ (rsbweb.nih.gov/ij/) with "Cell Counter" plug-in.
Wif-1 Staining
To quantify overall cytoplasmic staining intensity of astrocytes, positive brown pixels were detected by filtering RGB values B À 0.1 > R & G > B. Individual pixel brightness values were calculated as mean of the RGB values (R þ G þ B)/3. Because low-RGB values imply high-staining intensity and vice versa, the resulting vector was transformed (1 À x). The overall staining intensity was calculated by multiplication of the third quartile of individual values by the number of values, ie, number of detected pixels. The third quartile was robust against the influence of possibly false detected very bright pixels and minor numbers of dark brown pixels of individual cells. For quality control, images were ranked according to their calculated staining intensity values and reliable results in all images could be confirmed visually. As intended, individual cell populations heavily expressing Wif-1 did not affect the result of overall staining intensity in astrocytes. Numbers of these individual cells were counted in ImageJ.
For Ki65, intensely blue stained pixels of cell nuclei were identified by filtering RGB values R < B & R < G & R < median (B) * 0.7. Pixels with RGB values R > B & B < 0.35 & G < 0.55 were related to brown stained. "EBImage" package filters for dilation and erosion of blue and brown pixels followed by filling hulls marked the nuclei. Small and irregular false detected pixel groups were eliminated by appropriate filters of morphological features. Hence, marked nuclei with more than 10 brown pixels were categorized as immunohistochemically positively labeled. All images were visually controlled for reliable detection and grouping of blue and brown nuclei. The total number of nuclei in 11 out of 288 images with weak blue counter staining had to be corrected.
Statistical Analysis
The "R" package "Lattice" was used for data visualization (10) . To test the independence of 2 numeric variables, spearman tests were applied. The stratified spearman test of the package "coin" was computed to eliminate the influence of a third variable (11) .
RESULTS
Gene Expression Data
Statistical analysis of "Rembrandt" gene expression data revealed 4299 (p < 0.0001) and 2124 (p < 10À9) genes, respectively, that were significantly downregulated in both, in astrocytoma (WHO grade II) and in GBM, compared with non-neoplastic brain tissue. The merge with 24 genes with tumor suppressor function and DNA methylation revealed 5 remaining genes (APC, CDH13, PTEN, RARB, and WIF1). Out of these, WIF-1 was identified as the most consistent downregulated gene by boxplot analysis.
Subsequent analysis of all known secreted Wntantagonists, including DKK protein family and sFRP family members, exhibited none of these genes significantly deregulated. Only DKK3 and SFRP1 showed a tendency to be expressed at lower levels in astrocytoma (WHO Grades II and III) and in GBM compared with normal brain (Fig. 1) .
Wif-1 Expression by Astrocytoma Tumor Cells and Native Individual Cells
In total, 288 astrocytoma (WHO Grades I-IV) tissue regions, stratified in terms of WHO grade and tumor region were analyzed. As expected from gene analysis data, the overall IHC staining intensity for Wif-1 was high in 25 peritumoral non-neoplastic regions, reflecting high-protein expression levels ( Fig. 2A-C) . Moreover, distinct non-neoplastic cells of satellitosis in cerebral cortex exhibited strong Wif-1 staining in cytoplasm ( Fig. 2A) . Complementary, non-neoplastic reactive astrocytes, detected in individual areas of tumor periphery, exhibited intense cytoplasmic Wif-1 staining (Fig. 2C) .
In contrast, Wif-1 expression by astrocytes was found to be weak in low-grade gliomas in the tumor centers (102 regions) and weaker or in certain cases immunohistochemically undetectable in high-grade gliomas (128 regions), reflecting a further loss of expression by tumor progression (Fig. 2D-G) .
Within 288 astrocytoma ROIs, tumor areas with partially numerous small intensely Wif-1-expressing cells were detected. These smaller cells, located in tumor centers and at invasive margins of astrocytomas, were characterized by a few short cytoplasmic processes, morphologically resembling oligodendrocytes (Fig. 3A, E, Q) . Additionally, minor numbers of Wif-1-stained pre-existing neurons and reactive astrocytes were observed.
Because oligodendrocytes and microglial cells share morphological characteristics, consecutive sections of 10 samples with the densest infiltrates of small Wif-1-expressing cells were further analyzed. Consecutive sections were immunohistochemically stained for MAP-2 and Olig2, ie, proteins expressed by oligodendrocytes and oligodendroglioma cells (1) , and for the microglia marker Iba-1 (Fig. 3B-D, F-H) . Then, corresponding areas of 20 ROIs were evaluated for Wif-1-positive cells with morphological features of oligodendrocytes. Quantitative analysis revealed that the high numbers of anti-Wif-1-positive oligodendrocyte-like cells were significantly correlated with high numbers of MAP-2-and Olig2-positive cells (Wilcoxon-Mann-Whitney tests, p < 0.01). In contrast, only a few microglial cells could be detected with Iba-1. These data strengthened the hypothesis that Wif-1-positive cells represent oligodendrocytes. This approach was considered as most appropriate because there currently is no entirely specific marker for oligodendrocytes available.
With respect to the revised WHO classification (1), the astrocytomas were immunohistochemically tested for R132H mutation status of IDH1. Among WHO Grade II and III tumors, 77% carried the R132H mutation. Interestingly, the mutation status correlated positively with the density of Wif-1-positive oligodendrocytes in the tumors (Wilcoxon rank sum test, p < 0.05). Furthermore, IDH mutated astrocytomas were applied to verify the proposed non-neoplastic oligodendrocyte origin of Wif-1-positive cells. Therefore, double stainings with WIF-1 and IDH1 R132H or Iba1 were performed. In these stainings neither Iba-1-positive microglial cells, nor R132H mutated astrocytic tumor cells showed coexpression with Wif-1 (Fig. 3I-L) .
To confirm the non-neoplastic origin of Wif-1-positive oligodendrocytes in astrocytomas, 10 oligodendroglioma samples (7 WHO Grade II and 3 WHO Grade III) were stained with anti-Wif-1, -MAP-2, and -Olig2 antibodies. In accordance the WHO classification (1), the majority of tumor cells displayed specific positive reaction for MAP-2 and Olig2 ( Fig. 3O, P) . However, the Wif-1 staining in the neoplastic oligodendroglioma cells was overall weak, comparable to that in diffuse and anaplastic astrocytomas (Fig. 3N) . Notably, scattered non-neoplastic intensely Wif-1-expressing cells, as in astrocytomas, were not observed in the analyzed oligodendroglioma samples.
In summary, these data support the oligondroglial origin of intensely Wif-1-expressing cells in astrocytomas. Furthermore, the data highlight a non-neoplastic, native phenotype.
Quantification of immunohistochemical reactions by image analysis confirmed consistent high levels of Wif-1 expression in non-neoplastic astrocytes, especially adjacent to better demarcated GBMs (Fig. 4A) . Otherwise, the Wif-1 expression levels were considerably diminished in the invasion margins of diffusely infiltrating tumors and consistently very low in the tumor centers. Anaplastic astrocytoma regions exhibited the weakest overall staining intensities; Wif-1 expression was preserved on a low level in sarcomatoid differentiated tumor areas in GBMs (data not shown). In typically well-demarcated pilocytic astrocytomas, areas of non-neoplastic tissue, or invasion margin were not present in the surgical tumor specimens.
The numbers of Wif-1-positive oligodendrocytes per ROI in astrocytomas (WHO Grades I-IV) are shown in Figure 4B .
The densest infiltrates were detected in diffuse astrocytomas in tumor centers, whereas pilocytic astrocytomas and GBMs exhibited negligible cell numbers. Pronounced infiltrates were also observed at the invasion margins with highest densities at the periphery of GBMs.
Correlation of Wif-1 Expression and Proliferation Indices
Next, we investigated possible correlations between Wif-1 expression and proliferation. Corresponding images of Wif-1 and Ki67 stainings attracted attention to very low-proliferative activity in tumor areas with numerous Wif-1-positive oligodendrocytes. On the contrary, in their absence the proliferative activity appeared considerably higher (Fig. 3Q-T) . Scatter plots of quantified values are shown in Figure 5 . In tumor centers, a partial correlation between Ki67 index and Wif-1 expression in astrocytes was observed (Fig. 5A) . However, the proliferation index appears to be negatively associated with the numbers of Wif-1-positive oligodendrocytes in the tumors (Fig. 5B ). These findings were pronounced when tumor subgroups were analyzed.
The statistical analyses with Spearman tests (Columns 1 and 2) and Stratified spearman tests (Columns 3 and 4) are summarized in Table. The proliferation index correlated highly significant (p < 10eÀ9) with the numbers of Wif-1-positive oligodendrocytes when analyzed for all investigated regions and for tumor centers. After stratification by WHO grade, the most significant correlation was identified in tumor centers of anaplastic astrocytoma and diffuse astrocytoma (p ¼ 2.21eÀ5 and 5.30eÀ4, respectively). However, there was no significant correlation between Wif-1 expression in astrocytes and proliferation index in any of these groups (p > 0.2). In GBM exhibiting minor numbers of Wif-1-positive oligodendrocytes, both correlations were less distinct but remained significant (p < 0.01). In pilocytic astrocytomas (with negligible numbers of Wif-1-positive oligodendrocytes), only the correlation with Wif-1 expression in tumor cells remained significant (p < 0.05).
In addition, stratified Spearman tests were calculated to eliminate possible dependencies between Wif-1 expression in astrocytes and numbers of positive oligodendrocytes. All correlations with oligodendrocyte cell numbers remained significant after stratification by Wif-1 expression in astrocytoma tumor cells. However, none of the correlations with Wif-1 expression in tumor cells remained significant after stratification by Wif-1-positive oligodendrocyte cell numbers. When data distribution exhibited pronounced skewness, the calculation of stratified Spearman tests could not be performed, as indicated by "stratification not possible."
DISCUSSION
The Wnt/b-catenin signaling pathway is a major regulator of cell proliferation and differentiation. This pathway controls cell migration in embryogenesis and tissue homeostasis in adults. The Wnt/b-catenin pathway is activated by the binding of a Wnt ligand to a transmembrane Frizzled (Fz) receptor and its coreceptor, most often LRP6. Together with the recruited scaffolding protein (Dvl), LRP6 is phosphorylated and activated and the Axin complex is linked to the receptors. These events induce inhibition of Axin-mediated b-catenin phosphorylation and stabilization of b-catenin. Stabilized b-catenin accumulates and shifts to the nucleus to form complexes with TCF/LEF that activate Wnt target gene expression (12) .
Wnt pathway signaling can be inhibited by the secreted Wnt antagonists, secreted Frizzled-Related Proteins (sFRPs), Dickkopf proteins (Dkk), and Wnt inhibitory factor-1 (Wif-1) (13) . Members of the secreted Frizzled-Related Protein family antagonize Wnt/b-catenin signaling by forming complexes with the Fz receptors or by sequestering Wnt glycoproteins (14) while members of the Dickkopf family bind to LRP5/6 causing disruption of the Wnt/Fz/LRP complex (12) . The endogenous Wnt antagonist WIF-1 directly binds to extracellular Wnt ligands thereby preventing their interaction with the receptors and leading to b-catenin degradation (15, 16) .
Aberrant activation of the Wnt pathway is a key feature of many malignant tumors. The pronounced expression of multiple Wnt target genes such as c-myc, c-jun, and cyclin D1 participates in angiogenesis and metastasis (12, 17, 18) . In astrocytomas, Wnt signaling has been shown to be generally activated and aberrant high protein expression of b-catenin, Wnt-2, and Wnt-5a was correlated positively with tumor grade and negatively with prognosis (19) (20) (21) (22) .
Silencing of the secreted Wnt antagonist WIF-1 has been reported in carcinomas of the gastrointestinal tract, breast, lung, prostate, bladder, kidney, and nasopharynx (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) , in (34) , and hematologic neoplasms (35, 36) . In astrocytomas and GBMs, frequent downregulation of WIF-1 mRNA expression by promoter hypermethylation has been reported; the diminished WIF-1 mRNA levels and the associated lower expression of WIF-1 protein in tumor cells were inversely associated with WHO tumor grade (37) (38) (39) (40) (41) (42) . Interestingly in GBM, a methylated WIF-1 promoter was only found in 26% of samples but no mutations in the gene; thus WIF-1 silencing by promoter hypermethylation and genomic deletion was suggested (40) . Moreover, a partially maintained Wif-1 protein expression was reported to be beneficial for survival in patients with GBM (42).
WIF-1 Expression
The present study has confirmed pronounced and most relevant, consistent diminished mRNA levels of WIF-1 in gene expression data of astrocytoma and GBM. It is noteworthy that the mRNA levels of other secreted Wnt antagonists were found to be not significantly deregulated. Furthermore, consistent low protein expression of Wif-1 in astrocytoma and GBM tumor cells compared with normal brain was confirmed by independent analysis of numerous tumor regions. Importantly, the quantification of staining intensities with aid of image analysis eliminated observer bias.
Based on the present data, we highlight the potential of Wif-1 as a diagnostic marker in brain tumor pathology. We suggest that immunohistochemistry can be used for the detection of non-neoplastic astrocytes with intense Wif-1 staining to discriminate them from astrocytoma tumor cells with very weak or lack of staining. In particular, this staining could be beneficial in cases with questionable tumor cell infiltrates not carrying mutations that can be identified with specific antibodies.
Moreover, our analysis of numerous astrocytoma tumor regions uncovered tumor areas with in part dense infiltrates of Wif-1-expressing native, non-neoplastic oligodendrocytes. Reactive non-neoplastic cells within astrocytic tumors or at their invasive margins are not an unexpected finding. In fact, the numerous reactive oligodendrocytes could be identified as distinct and non-neoplastic based on Wif-1 immunostaining. Given that the scattered Wif-1-positive oligodendrocytes in astrocytomas were characterized as non-neoplastic and tumor cells of oligodendrogliomas overall showed very weak staining, it can be assumed that native or reactive oligodendrocytes can be distinguished from their neoplastic counterparts using Wif-1 immunostaining. Furthermore, it could be determined whether tumors that previously were classified as "oligoastrocytomas" harbor higher numbers of Wif-1-positive native oligodendrocytes.
Wif-1 and Proliferation
Activation of the Wnt pathway due to loss of the antagonist WIF1 has been reported in astrocytomas (37) (38) (39) (40) (41) (42) . It has been assumed that increased tumor cell proliferation is related to diminished WIF1 expression in tumor cells. In our detailed histological analysis of multiple tumor regions of astrocytomas (WHO Grades I-IV) we found evidence in support of this hypothesis in GBM and genetically different pilocytic astrocytomas. However, in the present study, we identified Wif-1-expressing oligodendrocytes in astrocytomas and showed that the astrocytoma tumor cell proliferation is significantly associated with numbers of the non-neoplastic oligodendrocytes. The most significant correlation of Wif-1-positive oligodendrocytes and proliferation index was observed in diffuse and anaplastic astrocytomas whereas partially maintained Wif-1 expression in tumor cells was not significantly associated with proliferative activity in these entities. Whereas GBMs and pilocytic astrocytomas exhibited only minor numbers of Wif-1-positive oligodendrocytes that could interfere with proliferation, the correlation of proliferation and the few Wif-1-positive oligodendrocytes was still significant in GBM.
Several in vitro and in vivo studies have investigated the functional effects of WIF1 expression in tumor cells. For example, in colorectal cancer cells and in xenograft mouse models of malignant melanoma, the restoration of WIF1 attenuated Wnt signaling, inhibited cell growth, and induced apoptosis (43, 44) . Potent antitumor activity of WIF1 through inhibition of Wnt signaling was also reported in hepatocellular carcinoma, prostate cancer and in an orthotopic osteosarcoma mouse model, resulting in increased apoptosis rate, impaired tumor vascularization and decreased capacity of cell migration, invasion and metastasis (17, 45, 46) . Additionally, WIF1 reexpression in cervical cancer induced cell cycle arrest, apoptosis and WIF1-treated tumors had well-defined borders (47) . Most relevant, WIF1 has been shown to regulate cell cycle and proliferation in primary GBM and GBM cell lines. In this study, Wif-1 overexpression could suppress GBM cell growth and tumor cells treated with exogenous WIF1 arrested in the G0/G1 phase (41) . Furthermore, in GBM cells a senescencelike growth arrest could be induced by the overexpression of WIF1 (40) .
Based on the reported functionalities of WIF1 and Wnt signaling, it is tempting to speculate that Wif-1 expressing native oligodendrocytes may contribute to inhibition of tumor cell proliferation and the invasion of astrocytoma tumor cells. Biologically this observation can be explained most likely by paracrine signaling. Although paracrine Wnt signaling by stroma cells of human tumors was discussed in prostate cancer (48) , to the authors' knowledge the present study indicates for the first time that a human cell type itself could foster antitumoral activity.
Therapeutic Potential of Wif-1
Several authors have reported that Wif-1 treatment of malignant tumor cells or gene transfer reduced proliferation, induced apoptosis, and inhibited neovascularization and metastasis (17, 41, . Also the inhibition of the Wnt canonical pathway by WIF1 promoter demethylation with procaine and procainamide or epigallocatechin-3-gallate was suggested (49) .
As mentioned above, in GBM cells a senescence-like growth arrest or a cell cycle arrest in the G0/G1 phase was induced by overexpression of WIF-1 (40, 41) . Furthermore, Norcantharidin induced promoter demethylation of WIF1, inhibited glioma cell proliferation, induced apoptosis and cell cycle arrest, and suppressed cell migration and invasion (50) .
The promising in vitro and in vivo results in various tumors including astrocytomas and GBM are now complemented by the observation that tumor cell proliferation is decreased in the presence of Wif-1-expressing native oligodendrocytes in human astrocytomas.
Taken together, therapeutic regimens of astrocytoma and GBM could benefit from additional administration of Wif-1. As an endogenous protein Wif-1 might represent an interesting therapeutic approach with expected minimal side effects, a therapeutic concept comparable to Insulin or hormone therapy. However, further studies are needed to prove this hypothesis.
